Summit Therapeutics (SMMT) Income from Non-Controlling Interests (2023 - 2024)
Summit Therapeutics (SMMT) posted Income from Non-Controlling Interests of $11000.0 for Q1 2024, down 59.26% on a QoQ basis from $27000.0 in Q4 2023, and down 98.86% year-over-year from $968000.0 in Q2 2023.
Summit Therapeutics (SMMT) Income from Non-Controlling Interests (2023 - 2024) Analysis & Trends
Summit Therapeutics' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $11000.0 for Q1 2024.
- Quarterly Income from Non-Controlling Interests fell 98.86% year-over-year to $11000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$921000.0 (down 195.14% YoY) and the FY2023 annual result came in at $36000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was $11000.0 for Q1 2024 at Summit Therapeutics, down from $27000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $968000.0 in Q1 2023 and bottomed at -$965000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | -965,000.00 |
| Mar 31, 2023 | 968,000.00 |